TRPV1 and type 2 diabetes mellitus: In rodent models of T2DM, pharmacological blockade of TRPV1 by small-molecule antagonists inhibited calcitonin gene-related peptide (CGRP) secretion, stimulated insulin secretion, reduced insulin resistance and prevented disease progression (Refs 15, 16, 17).